AMD3100 accelerates reendothelialization of neointima in rabbit saccular aneurysm after flow diverter treatment.

Related Articles

AMD3100 accelerates reendothelialization of neointima in rabbit saccular aneurysm after flow diverter treatment.

World Neurosurg. 2017 Jul 29;:

Authors: Li Z, Zhao R, Fang X, Zhou J, Jiang G, Huang Q, Liu J

Abstract
OBJECTIVE: To inspect the role of AMD3100 that acts as an antagonist of SDF-1/CXCR4 on the formation of neointima in rabbit saccular aneurysm after flow diverter (FD) treatment.
METHODS: Twenty saccular aneurysm models were established by using porcine pancreatic elastase. Three weeks later, a FDs of Tubridge was implanted into the saccular aneurysm. All treated models were immediately divided into two groups: the AMD3100 group was subcutaneously injected with AMD3100 (5 mg/kg per day), while control group with saline. Morphology and thickness of the neointima were investigated 2 and 4 weeks after FD treatment, using hard tissue section and masson trichrome staining. Scanning electron microscope (SEM) was used to observe endothelial-like cells, and fluorescence quantitative PCR was used to determine mRNA expression of neointima biomarkers, such as KDR, VE-cadherin, CD34, Tie2.
RESULTS: Two and four weeks after FD treatment, the AMD3100 group had more endothelial-like cells than the control group in the neointima. Masson trichrome staining showed that the neointima in the AMD3100 group was more intact and thicker than that the control group. Furthermore, increased mRNA levels of KDR, VE-cadherin, Tie2 in the neointima were found in AMD3100 group compared with control group.
CONCLUSIONS: Interval use of AMD3100 promotes the formation of neointima in rabbit saccular aneurysm and facilitates the endothelialization of the neointima after FD treatment.

PMID: 28765024 [PubMed - as supplied by publisher]

from #PM All via ola Kala on Inoreader http://ift.tt/2vlfDcZ